CoChat
Sign Up
Cited by 174Fatty Acid Research and HealthEicosanoids and Hypertension PharmacologyInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Cytochrome P450–dependent metabolism of ω-6 and ω-3 long-chain polyunsaturated fatty acids

Arnold, Cosima, Konkel, Anne, Fischer, Robert, Schunck, Wolf-Hagen·2010·Pharmacological Reports
DOI 10.1016/s1734-1140(10)70311-x
Open this paper in CoChat — free account

Abstract

Dietary fish oil omega-3 fatty acids (n-3 PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), protect against arrhythmia and sudden cardiac death using largely unknown mechanisms. EPA and DHA may serve as efficient alternative substrates of arachidonic acid (AA) metabolizing cytochrome P450 (CYP) enzymes. For many of the CYP isoforms, the n-3 PUFAs are the preferred substrates. Moreover, the CYP enzymes oxygenate EPA and DHA with largely different regioselectivities compared to AA. In particular, the omega-3 double bond that distinguishes EPA and DHA from AA is a preferred site of CYP-catalyzed epoxidation reactions. Given the pivotal role of CYP-dependent AA metabolites in the regulation of vascular, renal and cardiac functions, their replacement by unique sets of epoxy- and hydroxy-metabolites derived from EPA and DHA may have far-reaching physiological implications. The currently available data suggest that some of the vasculo- and cardioprotective effects attributed to dietary n-3 PUFAs may be mediated by CYP-dependent metabolites of EPA and DHA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1734-1140(10)70311-x

Cites

0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 101

  1. 1999, results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell ‘Infarto miocardico, Lancet, 354, 447, 10.1016/S0140-6736(99)07072-5 · DOI · Paper page
  2. Abdukeyum, 2008, Dietary (n-3) long-chain polyunsaturated fatty acids inhibit ischemia and reperfusion arrhythmias and infarction in rat heart not enhanced by ischemic preconditioning, J Nutr, 138, 1902, 10.1093/jn/138.10.1902 · DOI
  3. Ai, 2007, Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo, Proc Natl Acad Sci USA, 104, 9018, 10.1073/pnas.0703229104 · DOI
  4. Ai, 2009, Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy, Proc Natl Acad Sci USA, 106, 564, 10.1073/pnas.0811022106 · DOI
  5. Bang, 1976, The composition of food consumed by Greenland Eskimos, Acta Med Scand, 200, 69, 10.1111/j.0954-6820.1976.tb08198.x · DOI
  6. Barbosa-Sicard, 2005, Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily, Biochem Biophys Res Commun, 329, 1275, 10.1016/j.bbrc.2005.02.103 · DOI
  7. Blanton, 2006, Nitric oxide/cytochrome P450 interactions in cyclosporin A-induced effects in the rat, J Hypertens, 24, 1865, 10.1097/01.hjh.0000242412.88653.f2 · DOI
  8. Calder, 2006, Polyunsaturated fatty acids and inflammation, Prostaglandins Leukot Essent Fatty Acids, 75, 197, 10.1016/j.plefa.2006.05.012 · DOI
  9. Calo, 2005, N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial, J Am Coll Cardiol, 45, 1723, 10.1016/j.jacc.2005.02.079 · DOI
  10. Campbell, 1996, Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors, Circ Res, 78, 415, 10.1161/01.RES.78.3.415 · DOI
  11. Capdevila, 2002, Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases, Prostaglandins Other Lipid Mediat, 68–69, 325, 10.1016/S0090-6980(02)00038-2 · DOI
  12. Cheng, 2008, 20-hydroxyeico-satetraenoic acid causes endothelial dysfunction via eNOS uncoupling, Am J Physiol Heart Circ Physiol, 294, H1018, 10.1152/ajpheart.01172.2007 · DOI
  13. Dhanasekaran, 2008, Multiple anti-apoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardio-myocytes from hypoxia/anoxia, Am J Physiol Heart Circ Physiol, 294, H724, 10.1152/ajpheart.00979.2007 · DOI
  14. Dyerberg, 1978, Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?, Lancet, 2, 117, 10.1016/S0140-6736(78)91505-2 · DOI
  15. Fer, 2008, Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism, J Lipid Res, 49, 2379, 10.1194/jlr.M800199-JLR200 · DOI
  16. Fer, 2008, Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450, Arch Biochem Biophys, 471, 116, 10.1016/j.abb.2008.01.002 · DOI
  17. Fischer, 2008, Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension, Hypertension, 51, 540, 10.1161/HYPERTENSIONAHA.107.103143 · DOI
  18. Fisslthaler, 1999, Cytochrome P450 2C is an EDHF synthase in coronary arteries, Nature, 401, 493, 10.1038/46816 · DOI
  19. Fleming, 2007, Epoxyeicosatrienoic acids, cell signaling and angiogenesis, Prostaglandins Other Lipid Mediat, 82, 60, 10.1016/j.prostaglandins.2006.05.003 · DOI
  20. Fleming, 2008, Vascular cytochrome p450 enzymes: physiology and pathophysiology, Trends Cardiovasc Med, 18, 20, 10.1016/j.tcm.2007.11.002 · DOI
  21. Funk, 2001, Prostaglandins and leukotrienes: advances in eicosanoid biology, Science, 294, 1871, 10.1126/science.294.5548.1871 · DOI · Paper page
  22. Gross, 2004, Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel, J Mol Cell Cardiol, 37, 1245
  23. Gross, 2007, Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts, J Mol Cell Cardiol, 42, 687, 10.1016/j.yjmcc.2006.11.020 · DOI
  24. Gryglewski, 2008, Prostacyclin among prostanoids, Pharmacol Rep, 60, 3
  25. Gryglewski, 1979, Effects of all cis-5,8,11,14,17–eicosapentaenoic acid and PGH3 on platelet aggregation, Prostaglandins, 18, 453, 10.1016/S0090-6980(79)80063-5 · DOI
  26. Harmon, 2006, Oxygenation of ω-3 fatty acids by human cytochrome P450 4F3B: effect on 20-hydroxyeicosatetraenoic acid production, Prostaglandins Leukot Essent Fatty Acids, 75, 169, 10.1016/j.plefa.2006.05.005 · DOI
  27. Harris, 2008, Omega-3 fatty acids and coronary heart disease risk:clinical and mechanistic perspectives, Atherosclerosis, 197, 12, 10.1016/j.atherosclerosis.2007.11.008 · DOI · Paper page
  28. Hata, 2004, Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation, Pharmacol Ther, 103, 147, 10.1016/j.pharmthera.2004.06.003 · DOI
  29. He, 2004, Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies, Circulation, 109, 2705, 10.1161/01.CIR.0000132503.19410.6B · DOI · Paper page
  30. Hercule, 2007, The vasodilator 17,18-epoxyeicosatetraenoic acid targets the pore-forming BK α channel subunit in rodents, Exp Physiol, 92, 1067, 10.1113/expphysiol.2007.038166 · DOI
  31. Hercule, 2009, Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice, Arterioscler Thromb Vasc Biol, 29, 54, 10.1161/ATVBAHA.108.171298 · DOI
  32. Hoagland, 2003, Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats, Hypertension, 42, 669, 10.1161/01.HYP.0000084634.97353.1A · DOI
  33. Honeck, 2000, Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice, Hypertension, 36, 610, 10.1161/01.HYP.36.4.610 · DOI
  34. Hutchens, 2008, Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation, Resuscitation, 76, 89, 10.1016/j.resuscitation.2007.06.031 · DOI
  35. Imig, 2005, Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases, Am J Physiol Renal Physiol, 289, F496, 10.1152/ajprenal.00350.2004 · DOI
  36. Imig, 2002, Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension, Hypertension, 39, 690, 10.1161/hy0202.103788 · DOI
  37. Inceoglu, 2007, Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs), Prostaglandins Other Lipid Mediat, 82, 42, 10.1016/j.prostaglandins.2006.05.004 · DOI
  38. Ishizuka, 2008, 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-KB activation and the production of inflammatory cytokines in human endothelial cells, J Pharmacol Exp Ther, 324, 103, 10.1124/jpet.107.130336 · DOI
  39. Jiang, 2007, Cytochrome p450 epoxygenase promotes human cancer metastasis, Cancer Res, 67, 6665, 10.1158/0008-5472.CAN-06-3643 · DOI
  40. Jump, 2002, The biochemistry of n-3 polyunsaturated fatty acids, J Biol Chem, 277, 8755, 10.1074/jbc.R100062200 · DOI
  41. Jung, 2005, Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension, Hypertension, 45, 759, 10.1161/01.HYP.0000153792.29478.1d · DOI
  42. Karlgren, 2004, Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1, Biochem Biophys Res Commun, 315, 679, 10.1016/j.bbrc.2004.01.110 · DOI
  43. Keseru, 2008, Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response, FASEB J, 22, 4306, 10.1096/fj.08-112821 · DOI
  44. Kris-Etherton, 2002, Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease, Circulation, 106, 2747, 10.1161/01.CIR.0000038493.65177.94 · DOI · Paper page
  45. Lands, 2005, Dietary fat and health: the evidence and the politics of prevention: careful use of dietary fats can improve life and prevent disease, Ann NY Acad Sci, 1055, 179, 10.1196/annals.1323.028 · DOI · Paper page
  46. Lauterbach, 2002, Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators, Hypertension, 39, 609, 10.1161/hy0202.103293 · DOI
  47. Lavie, 2009, Omega-3 polyunsaturated fatty acids and cardiovascular diseases, J Am Coll Cardiol, 54, 585, 10.1016/j.jacc.2009.02.084 · DOI · Paper page
  48. Lee, 1999, Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes, J Physiol, 519, 153, 10.1111/j.1469-7793.1999.0153o.x · DOI
  49. Liclican, 2008, Failure to upregulate the adenosine2A receptor-epoxyeicosatrienoic acid pathway contributes to the development of hypertension in Dahl salt-sensitive rats, Am J Physiol Renal Physiol, 295, F1696, 10.1152/ajprenal.90502.2008 · DOI
  50. Loch, 2007, Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase, Cell Biochem Bio-phys, 47, 87, 10.1385/CBB:47:1:87 · DOI
  51. Loot, 2008, Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation, Cardiovasc Res, 80, 445, 10.1093/cvr/cvn207 · DOI
  52. Lu, 2001, Activation of ATP-sensitive K+ channels by epoxyeicosatri-enoic acids in rat cardiac ventricular myocytes, J Physiol, 537, 811, 10.1113/jphysiol.2001.012896 · DOI
  53. Lu, 2002, Stereospecific activation of cardiac ATP-sensitive K+ channels by epoxyeicosatrienoic acids: a structural determinant study, Mol Pharmacol, 62, 1076, 10.1124/mol.62.5.1076 · DOI
  54. Matthan, 2005, A systematic review and metaanalysis of the impact of ω-3 fatty acids on selected arrhythmia outcomes in animal models, Metab Clin Exp, 54, 1557, 10.1016/j.metabol.2005.05.026 · DOI
  55. McGiff, 1999, 20–HETE and the kidney: resolution of old problems and new beginnings, Am J Physiol, 277, R607
  56. Monti, 2008, Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease, Nat Genet, 40, 529, 10.1038/ng.129 · DOI
  57. Morin, 2009, Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung, Am J Physiol Lung Cell Mol Physiol, 296, L130, 10.1152/ajplung.90436.2008 · DOI
  58. Motoki, 2008, Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo, Am J Physiol Heart Circ Physiol, 295, H2128, 10.1152/ajpheart.00428.2008 · DOI
  59. Mozaffarian, 2008, Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death, Am J Clin Nutr, 87, 1991S, 10.1093/ajcn/87.6.1991S · DOI · Paper page
  60. Muller, 2007, Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation, Biochem J, 403, 109, 10.1042/BJ20061328 · DOI
  61. Muller, 2004, A peroxisome proliferator-activated receptor-a activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury, Am J Pathol, 164, 521, 10.1016/S0002-9440(10)63142-2 · DOI
  62. Nguyen, 1999, Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors, Am J Physiol, 276, R1691
  63. Nithipatikom, 2006, Effects of selective inhibition of cytochrome P-450 ω-hydroxylases and ischemic preconditioning in myocardial protection, Am J Physiol Heart Circ Physiol, 290, H500, 10.1152/ajpheart.00918.2005 · DOI
  64. Nithipatikom, 2004, Inhibition of cytochrome P450 ω-hydroxylase: a novel endogenous cardioprotective pathway, Circ Res, 95, e65, 10.1161/01.RES.0000146277.62128.6f · DOI
  65. Node, 1999, Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids, Science, 285, 1276, 10.1126/science.285.5431.1276 · DOI
  66. Peters-Golden, 2007, Leukotrienes, N Engl J Med, 357, 1841, 10.1056/NEJMra071371 · DOI
  67. Revermann, 2009, Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats, J Hypertens, 27, 322, 10.1097/HJH.0b013e32831aedfa · DOI
  68. Roman, 2002, P-450 metabolites of arachidonic acid in the control of cardiovascular function, Physiol Rev, 82, 131, 10.1152/physrev.00021.2001 · DOI
  69. Roman, 1997, Renal P450 metabolites of arachidonic acid and the development of hypertension in Dahl salt-sensitive rats, Am J Hypertens, 10, 63S, 10.1016/S0895-7061(97)00077-0 · DOI
  70. Russo, 2009, Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention, Biochem Pharmacol, 77, 937, 10.1016/j.bcp.2008.10.020 · DOI
  71. Schwarz, 2005, Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns, Biochem Bio-phys Res Commun, 336, 779, 10.1016/j.bbrc.2005.08.172 · DOI
  72. Schwarz, 2004, Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid, Biochem Pharmacol, 67, 1445, 10.1016/j.bcp.2003.12.023 · DOI
  73. Seubert, 2004, Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway, Circ Res, 95, 506, 10.1161/01.RES.0000139436.89654.c8 · DOI
  74. Seubert, 2006, Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function, Circ Res, 99, 442, 10.1161/01.RES.0000237390.92932.37 · DOI
  75. Seubert, 2007, Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury, Prostaglandins Other Lipid Mediat, 82, 50, 10.1016/j.prostaglandins.2006.05.017 · DOI
  76. Simopoulos, 2008, The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases, Exp Biol Med (Maywood), 233, 674, 10.3181/0711-MR-311 · DOI
  77. Simpkins, 2009, Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection, Am J Pathol, 174, 2086, 10.2353/ajpath.2009.080544 · DOI
  78. Singh, 2007, Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgeninduced hypertension, Hypertension, 50, 123, 10.1161/HYPERTENSIONAHA.107.089599 · DOI
  79. Singh, 2008, Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension, Pharmacol Rep, 60, 29
  80. Smith, 2005, Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor, Proc Natl Acad Sci USA, 102, 2186, 10.1073/pnas.0409591102 · DOI
  81. Spector, 2009, Arachidonic acid cytochrome P450 epoxygenase pathway, J Lipid Res, 50, S52, 10.1194/jlr.R800038-JLR200 · DOI
  82. Spiecker, 2005, Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids, Arch Biochem Biophys, 433, 413, 10.1016/j.abb.2004.10.009 · DOI
  83. Stark, 2005, Oxygenation of polyunsaturated long chain fatty acids by recombinant CYP4F8 and CYP4F12 and catalytic importance of Tyr-125 and Gly-328 of CYP4F8, Arch Biochem Biophys, 441, 174, 10.1016/j.abb.2005.07.003 · DOI
  84. Sun, 2006, Low Na intake suppresses expression of CYP2C23 and arachidonic acid-induced inhibition of ENaC, Am J Physiol Renal Physiol, 291, F1192, 10.1152/ajprenal.00112.2006 · DOI
  85. Terano, 1984, Biosynthesis and biological activity of leukotriene B5, Prostaglandins, 27, 217, 10.1016/0090-6980(84)90075-3 · DOI
  86. Van Rollins, 1988, Oxidation of 5,8,11,14,17-eicosapentaenoic acid by hepatic and renal microsomes, Biochim Biophys Acta, 966, 133, 10.1016/0304-4165(88)90137-7 · DOI
  87. VanRollins, 1984, Oxidation of docosahexaenoic acid by rat liver microsomes, J Biol Chem, 259, 5776, 10.1016/S0021-9258(18)91081-1 · DOI
  88. von Schacky, 2009, Use of red blood cell fatty-acid profiles as biomarkers in cardiac disease, Biomark Med, 3, 25, 10.2217/17520363.3.1.25 · DOI
  89. von Schacky, 2007, Cardiovascular benefits of omega-3 fatty acids, Cardiovasc Res, 73, 310, 10.1016/j.cardiores.2006.08.019 · DOI
  90. Wang, 2003, Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways, J Pharmacol Exp Ther, 307, 753, 10.1124/jpet.103.052787 · DOI
  91. Wang, 2006, Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus, Circ Res, 98, 962, 10.1161/01.RES.0000217283.98806.a6 · DOI
  92. Wu, 1996, Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart, J Biol Chem, 271, 3460, 10.1074/jbc.271.7.3460 · DOI
  93. Xiao, 2007, Cyclic AMP-dependent modulation of cardiac L-type Ca2+ and transient outward K+ channel activities by epoxyeicosatrienoic acids, Prostaglandins Other Lipid Mediat, 82, 11, 10.1016/j.prostaglandins.2006.05.023 · DOI
  94. Xiao, 1998, Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells, J Physiol, 508, 777, 10.1111/j.1469-7793.1998.777bp.x · DOI
  95. Xiao, 2004, Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2, Mol Pharmacol, 66, 1607, 10.1124/mol.104.004150 · DOI
  96. Xu, 2006, Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors, Proc Natl Acad Sci USA, 103, 18733, 10.1073/pnas.0609158103 · DOI
  97. Yang, 2007, Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-a via MAPK and PI3K/Akt signaling pathways, Am J Physiol Heart Circ Physiol, 293, H142, 10.1152/ajpheart.00783.2006 · DOI
  98. Yang, 2008, Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125I-14,15-epoxyeicosa-8(Z)-enoic acid, J Pharmacol Exp Ther, 324, 1019, 10.1124/jpet.107.129577 · DOI
  99. Ye, 2002, Cytochrome P-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels, J Pharmacol Exp Ther, 303, 768, 10.1124/jpet.303.2.768 · DOI
  100. Yu, 2000, Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids, Circ Res, 87, 992, 10.1161/01.RES.87.11.992 · DOI
  101. Zhang, 2001, EET homologs potently dilate coronary microvessels and activate BKCa channels, Am J Physiol Heart Circ Physiol, 280, H2430, 10.1152/ajpheart.2001.280.6.H2430 · DOI

Cited by

Sorted by citations

Items 101–145 of 145

Metadata

Authors
Arnold, C., Konkel, A., Fischer, R., & Schunck, W.-H.
Affiliations
Max Delbrück Center (DE)
Corresponding author
Schunck, Wolf-Hagen
ORCID
Venue
Pharmacological Reports
Publisher
Springer Science and Business Media LLC
Published
2010-05
Volume
62
Issue
3
Pages
536-547
ISSN
1734-1140 (ISSN-L)
DOI
10.1016/s1734-1140(10)70311-x
OpenAlex
W1998719368
Cited by
174
References
111
Citations by year
2026: 2 · 2025: 10 · 2024: 6 · 2023: 13 · 2022: 9 · 2021: 8 · 2020: 10 · 2019: 10 · 2018: 12 · 2017: 13 · 2016: 10 · 2015: 11 · 2014: 19 · 2013: 12 · 2012: 15
FWCI
1.47
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Pharmacological Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
cytochrome P450, omega-3 fatty acids, omega-6 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid metabolism, fatty acid epoxidation, regioselectivity, epoxy fatty acids, hydroxy fatty acids, fish oil, cardioprotection, vascular protection, sudden cardiac death, cardiac arrhythmias
MeSH terms
Cytochrome P-450 CYP2J2, Animals, Cardiotonic Agents, Cardiovascular Diseases, Cytochrome P-450 Enzyme System, Docosahexaenoic Acids, Epoxide Hydrolases, Humans, Hydroxyeicosatetraenoic Acids, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Arachidonic Acid, Death, Sudden, Cardiac, Cytochrome P-450 CYP1A1, Cytochrome P-450 CYP2E1, Fatty Acids, Omega-6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review